Emerging Immunotherapy Approaches for Treating Prostate Cancer
被引:10
|
作者:
Meng, Lingbin
论文数: 0引用数: 0
h-index: 0
机构:
Ohio State Univ, Comprehens Canc Ctr, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USAOhio State Univ, Comprehens Canc Ctr, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA
Meng, Lingbin
[1
]
Yang, Yuanquan
论文数: 0引用数: 0
h-index: 0
机构:
Ohio State Univ, Comprehens Canc Ctr, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USAOhio State Univ, Comprehens Canc Ctr, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA
Yang, Yuanquan
[1
]
Mortazavi, Amir
论文数: 0引用数: 0
h-index: 0
机构:
Ohio State Univ, Comprehens Canc Ctr, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USAOhio State Univ, Comprehens Canc Ctr, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA
Mortazavi, Amir
[1
]
Zhang, Jingsong
论文数: 0引用数: 0
h-index: 0
机构:
Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Genitourinary Oncol, 12902 USF Magnolia Dr, Tampa, FL 33612 USAOhio State Univ, Comprehens Canc Ctr, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA
Zhang, Jingsong
[2
]
机构:
[1] Ohio State Univ, Comprehens Canc Ctr, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA
[2] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Genitourinary Oncol, 12902 USF Magnolia Dr, Tampa, FL 33612 USA
immunotherapy;
prostate cancer;
immune checkpoint inhibitors;
bispecific antibodies;
CAR T cells;
vaccines;
cytokines;
immunotherapeutic combinations;
CAR-T-CELLS;
IMMUNE-CHECKPOINT;
DOUBLE-BLIND;
PHASE-III;
PLUS DOCETAXEL;
CLINICAL-TRIAL;
SIPULEUCEL-T;
TUMOR MICROENVIRONMENT;
DNA VACCINE;
ANTIGEN;
D O I:
10.3390/ijms241814347
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
Immunotherapy has emerged as an important approach for cancer treatment, but its clinical efficacy has been limited in prostate cancer compared to other malignancies. This review summarizes key immunotherapy strategies under evaluation for prostate cancer, including immune checkpoint inhibitors, bispecific T cell-engaging antibodies, chimeric antigen receptor (CAR) T cells, therapeutic vaccines, and cytokines. For each modality, the rationale stemming from preclinical studies is discussed along with outcomes from completed clinical trials and strategies to improve clinical efficacy that are being tested in ongoing clinical trials. Imperative endeavors include biomarker discovery for patient selection, deciphering resistance mechanisms, refining cellular therapies such as CAR T cells, and early-stage intervention were reviewed. These ongoing efforts instill optimism that immunotherapy may eventually deliver significant clinical benefits and expand treatment options for patients with advanced prostate cancer.
机构:
Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Div Canc Med, Houston, TX 77030 USAUniv Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Div Canc Med, Houston, TX 77030 USA
机构:
Univ Kansas, Med Ctr, Dept Urol, MS 3016,3901 Rainbow Blvd, Kansas City, KS 66160 USAUniv Kansas, Med Ctr, Dept Urol, MS 3016,3901 Rainbow Blvd, Kansas City, KS 66160 USA
Karan, Dev
Van Veldhuizen, Peter
论文数: 0引用数: 0
h-index: 0
机构:
Univ Kansas, Med Ctr, Div Hematol Oncol, Westwood, KS 66205 USAUniv Kansas, Med Ctr, Dept Urol, MS 3016,3901 Rainbow Blvd, Kansas City, KS 66160 USA